‘Twas the year of the M&A boom …
‘Twas the end of 2009, and in the ddn newsroom,
the editors and writers gathered to reflect on Big Pharma’s M&A boom.
In a rare moment of quiet, away from their desks,
visions of dollar signs loomed large and grotesque.
News of layoffs and job cuts rang in their ears,
but Big Pharma’s buyouts somehow overcame most analysts’ fears.
“The economy tanked, but Big Pharma prevailed,” said Amy Swinderman, sipping her Malbec.
“This year was a blur,” she sighed, “and my desk is a wreck!”
“Pfizer/Wyeth, Merck/Schering, Roche/Genentech, Gilead/CV Therapeutics,” mused Jeff Bouley, swirling the scotch in his crystal.
“Billions of dollars spent; lots of midnight deadlines,” he recalled, seeming almost wistful.
“Plenty of multimillion dollar deals, too,” Dave Hutton chimed in.
Clad in his new LeBron James jersey, the names “J&J” and “BMS” gave him a grin.
Cracking open his Diet Pepsi, Dave added, “I also put Phase Forward on speed dial.
Yet the news wasn’t all good; I also covered many a failed drug trial.”
“I had beaucoup rendez-vous with sanofi-aventis,” added Lori Lesko, her keyboard littered with cookie.
“Laboratorios Kendrick, Medley, BiPar Sciences, Shantha, Fovea … to many an acquisition, the French pharma said, ‘oui.’”
“I’ve enjoyed this brief respite; it’s really been fun,” interrupted Lloyd Dunlap, wrapping gifts in red and green tissue.
“But Qiagen just bought SA Biosciences for $90 mil, so we’d better move on to our January issue!”
So from all of us at ddn—Amy, Jeff, Dave, Lloyd and Lori—
We wish you an even more successful 2010, and we look forward to telling your story.